Hikal Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ms9tzue6yurp7bt0b383bk46.pdf

Key Takeaways


Pharma Recovery & Quality Systems

Sameer Hiremath: "I think the FDA is that we've had a 25-year track record. This is our first FDA inspection that we've had a not so of favorable inspection. So we know exactly what is to be done."

New Business Segments: Animal Health & Personal Care


CDMO Pipeline & New Capabilities

Sameer Hiremath: "This is a permanent upgrade to our organizational DNA designed to ensure long-term operational resilience and excellence."

Crop Protection: Persistent Headwinds


Financial Position & Capital Allocation

Sameer Hiremath: "From FY '29 onwards, we should start seeing a reduction in overall debt, which is already reducing compared to where we were. We are not doing any major new capex or anything. It's debottlenecking, adding a production line here and there."

Margins & Operating Leverage

Sameer Hiremath: "So even the margins from a gross margin perspective, the new products have a slightly better gross margin than the historical gross margin of the company, number one. But that directly flows down to far better EBITDA because fixed cost absorption is already happening on the current base business."

Guidance & Commitments

CommitmentSpecificsTimeline
Pharma double-digit growthDouble-digit growth to begin in early part of FY27FY27
Personal Care meaningful revenueMeaningful revenue to commenceFY27
Personal Care product launches3–4 products to be commercializedFY27
Milvexian KSM launchSupply of key starting material for MilvexianFY27
Food & nutraceutical peak outputTwo custom products at peak outputFY27
Crop plant repurposing Phase IPhase I implementationNext 6 months
Crop plant repurposing Phase IIPhase II implementationNext 12 months after Phase I
HPAPI commercial plantCommercial-scale plant for HP APIs and ADCsFY28
Animal Health INR500 cr+ targetINR500 crores plus revenueNext 4–5 years
Debt reductionOverall debt to begin declining meaningfullyFY29 onwards
Capex FY26Approximately INR150 croresFY26

Key Metrics

MetricQ3 FY26
Consolidated revenue₹494 cr
Consolidated EBITDA₹83 cr, margin of 16.8%
Consolidated revenue (9M FY26)₹1,193 cr
Consolidated EBITDA (9M FY26)₹115 cr, margin of 9.6%
Profit before tax (adjusted)₹29 cr, grew 21% after adjusting for exceptional item
Exceptional item₹38 cr provision for new labour code charges notified Nov 21, 2025
Finance cost₹48 cr, reduction of 17% YoY
Capital expenditure (9M FY26)₹100 cr; full-year FY26 guidance cut to ₹150 cr from ₹200 cr
Debt-equity ratio0.58 as on Dec 31, 2025
Interim dividend₹0.2 per share, 10% of face value
Pharma division revenue₹337 cr
Pharma division EBIT₹41 cr, margin of 12.3%
Crop Protection division revenue₹157 cr
Crop Protection division EBIT₹5 cr, margin of 3%
Pharma volume growth~4% in Q3; double-digit volume growth expected to return
Animal Health gross margin45% to 50%, in line with company; NCE portfolio margins higher
Working capital reduction (9M FY26 vs Mar 25)~₹50 cr
HPAPI lab investment (Phase I)₹10–11 cr
Personal Care products commercialized in Q32 products; volume ramp-up over next 9–12 months
Pharma development pipeline (advanced stages)8 to 9 molecules
Crop Protection development pipeline8 products